Cixutumumab
Cixutumumab is a monoclonal antibody designed for the treatment of cancer. It targets the insulin-like growth factor 1 receptor (IGF-1R), which plays a pivotal role in the growth and survival of cancer cells. By inhibiting this receptor, cixutumumab aims to reduce tumor growth and proliferation.
Development and Mechanism[edit | edit source]
Cixutumumab was developed as part of a broader effort to target growth factor receptors in oncology. The IGF-1R is particularly significant in cancer biology as it influences several downstream signaling pathways, including those involved in cell survival (PI3K/AKT) and cell cycle progression (MAPK pathway). The antibody binds specifically to IGF-1R, blocking its activation and subsequent signaling, which can lead to the inhibition of cancer cell growth and induction of apoptosis.
Clinical Trials[edit | edit source]
Cixutumumab has been evaluated in various clinical trials for different types of cancers, including sarcoma, non-small cell lung cancer (NSCLC), and prostate cancer. These studies have focused on assessing its efficacy, both as a monotherapy and in combination with other chemotherapy agents. However, the results have been mixed, and as of the last updates, it has not received approval from regulatory bodies such as the Food and Drug Administration (FDA).
Safety and Side Effects[edit | edit source]
In clinical trials, cixutumumab was generally well tolerated, but some patients experienced side effects typical of agents targeting the IGF pathway. These included hyperglycemia, thrombocytopenia, and fatigue. The severity and incidence of these side effects varied among studies and patient populations.
Current Status and Future Directions[edit | edit source]
Research on cixutumumab is ongoing, with efforts focused on better understanding its mechanism, optimizing dosing strategies, and identifying patient populations that might benefit most from its use. Future studies are also likely to explore combinations of cixutumumab with newer targeted therapies and immunotherapy agents.
See Also[edit | edit source]
 | This medical article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
